FCR front-line therapy and quality of life in patients with
chronic lymphocytic leukemia

J 2017

FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia

KUTSCH, N., R. BUSCH, J. BAHLO, Jiří MAYER, M. HENSEL et. al.

Basic information

Original name

FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia

Authors

KUTSCH, N., R. BUSCH, J. BAHLO, Jiří MAYER, M. HENSEL, G. HOPFINGER, G. HESS, U. von GRUNHAGEN, C.M. WENDTNER, A.M. FINK, K. FISCHER, M. HALLEK and B. EICHHORST

Edition

LEUKEMIA & LYMPHOMA, LONDON, INFORMA HEALTHCARE, 2017, 1042-8194

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.644

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1080/10428194.2016.1190966

UT WoS

000388601000019

Keywords in English

Chemoimmunotherapy; CLL; FCR; HRQOL; quality of life

Abstract

V originále

The chemoimmunotherapy FCR (fludarabine and cyclophosphamide with rituximab) is the standard first-line treatment for physically fit chronic lymphocytic leukemia (CLL) patients. To assess the risks and benefits, we investigated health-related quality of life (HRQOL). 817 untreated CLL patients received either FC or FCR within the GCLLSG CLL8 trial. The European Organization for Research and Treatment of Cancer Quality of life Questionnaire C30 was sent to all patients at baseline, after 3, 6, and 12 months and then yearly as follow-up. A total of 769 (94%) of 817 patients completed at least one questionnaire. Comparing HRQOL of CLL patients with the general German population, CLL patients' health declined in most scales except for global health and pain. No major differences in HRQOL were found during treatment or follow-up between both treatment arms. Females were more likely to have treatment-related symptoms than males. Although FCR was associated with more side effects, this did not influence HRQOL. During follow-up after FCR only minor improvement of HRQOL compared with FC was assessed.

Citovat

KUTSCH, N., R. BUSCH, J. BAHLO, Jiří MAYER, M. HENSEL, G. HOPFINGER, G. HESS, U. von GRUNHAGEN, C.M. WENDTNER, A.M. FINK, K. FISCHER, M. HALLEK and B. EICHHORST. FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia. LEUKEMIA & LYMPHOMA. LONDON: INFORMA HEALTHCARE, 2017, vol. 58, No 2, p. 399-407. ISSN 1042-8194. Available from: https://dx.doi.org/10.1080/10428194.2016.1190966.

@article{1399041,
   author = {Kutsch, N. and Busch, R. and Bahlo, J. and Mayer, Jiří and Hensel, M. and Hopfinger, G. and Hess, G. and Grunhagen, U. von and Wendtner, C.M. and Fink, A.M. and Fischer, K. and Hallek, M. and Eichhorst, B.},
   article_location = {LONDON},
   article_number = {2},
   doi = {http://dx.doi.org/10.1080/10428194.2016.1190966},
   keywords = {Chemoimmunotherapy; CLL; FCR; HRQOL; quality of life},
   language = {eng},
   issn = {1042-8194},
   journal = {LEUKEMIA & LYMPHOMA},
   title = {FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia},
   url = {http://dx.doi.org/10.1080/10428194.2016.1190966},
   volume = {58},
   year = {2017}
}

TY  - JOUR
ID  - 1399041
AU  - Kutsch, N. - Busch, R. - Bahlo, J. - Mayer, Jiří - Hensel, M. - Hopfinger, G. - Hess, G. - Grunhagen, U. von - Wendtner, C.M. - Fink, A.M. - Fischer, K. - Hallek, M. - Eichhorst, B.
PY  - 2017
TI  - FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia
JF  - LEUKEMIA & LYMPHOMA
VL  - 58
IS  - 2
SP  - 399-407
EP  - 399-407
PB  - INFORMA HEALTHCARE
SN  - 10428194
KW  - Chemoimmunotherapy
KW  - CLL
KW  - FCR
KW  - HRQOL
KW  - quality of life
UR  - http://dx.doi.org/10.1080/10428194.2016.1190966
L2  - http://dx.doi.org/10.1080/10428194.2016.1190966
N2  - The chemoimmunotherapy FCR (fludarabine and cyclophosphamide with rituximab) is the standard first-line treatment for physically fit chronic lymphocytic leukemia (CLL) patients. To assess the risks and benefits, we investigated health-related quality of life (HRQOL). 817 untreated CLL patients received either FC or FCR within the GCLLSG CLL8 trial. The European Organization for Research and Treatment of Cancer Quality of life Questionnaire C30 was sent to all patients at baseline, after 3, 6, and 12 months and then yearly as follow-up. A total of 769 (94%) of 817 patients completed at least one questionnaire. Comparing HRQOL of CLL patients with the general German population, CLL patients' health declined in most scales except for global health and pain. No major differences in HRQOL were found during treatment or follow-up between both treatment arms. Females were more likely to have treatment-related symptoms than males. Although FCR was associated with more side effects, this did not influence HRQOL. During follow-up after FCR only minor improvement of HRQOL compared with FC was assessed.
ER  -

KUTSCH, N., R. BUSCH, J. BAHLO, Jiří MAYER, M. HENSEL, G. HOPFINGER, G. HESS, U. von GRUNHAGEN, C.M. WENDTNER, A.M. FINK, K. FISCHER, M. HALLEK and B. EICHHORST. FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia. \textit{LEUKEMIA \&{}amp; LYMPHOMA}. LONDON: INFORMA HEALTHCARE, 2017, vol.~58, No~2, p.~399-407. ISSN~1042-8194. Available from: https://dx.doi.org/10.1080/10428194.2016.1190966.

Detailed Information on Publication Record